AzTrials
AzTrials

Pudendal NeuralgiapelvicpainNCT05531500

Patient Reported Outcomes Following Interventional Procedures in Pelvic Pain

A study testing Injection and Radiofrequency in people with Pudendal Neuralgia, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The investigators aim from this study, to determine the safety and efficacy of pulsed radiofrequency in the management of pudendal neuralgia, compared to current a standard intervention, which is corticosteroid injection for PN, as part of multidisciplinary pain management. Read more about this study

Who is it for?
Ages 30 years and older
Conditions the study is for
Pudendal Neuralgia
What is being tested?
Injection and Radiofrequency
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
No sites listed yet
Study dates
9 Sep 2022to 30 May 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with chronic pain> 6 months
  • Patients aged > 18years
  • Patients with unilateral or bilateral regional pelvic pain withpudendal irritation diagnosed by a pain clinician and clinically indicated to undergo pudendal nerve block by a consultant experienced in the field.

Who cannot join

  • Known concurrent neurological or neurodegenerative disease, including those with impaired neurotransmission e.g. myasthenia gravis, multiple sclerosis, spinal cord injury etc
  • Pelvic surgery is expected within 3 months
  • Breastfeeding or pregnant women
  • Known current pelvic/pelvic organ infection or malignancy (Red flags)
  • Concurrent radiotherapy treatment to pelvis
  • Allergy/sensitivity to lidocaine anaesthetic or/ and corticosteroids therapy
  • Contraindication to receive a Pudendal nerve block eg high risk of bleeding
  • Active psychiatric or mental conditions ▪ Other uncontrolled medical condition

Trial locations and contacts

No sites are listed yet.

Medhat SA Farghaly, Master contact

2001095105568

medhatsradwan@aun.edu.eg

Saied M Elsawy, PhD contact

2001030072161

saeedelsawy17@aun.edu.eg

About this study

The investigators aim from this study, to determine the safety and efficacy of pulsed radiofrequency in the management of pudendal neuralgia, compared to current a standard intervention, which is corticosteroid injection for PN, as part of multidisciplinary pain management.

Read the detailed description

The aim of this study is toillustrate whether pulsed radiofrequency treatment is safe and effective intreating the chronic perineal pain associated with PN or pudendal nerve compression; and whether it can be used as an integral part of its multidisciplinary managementBased on literature, the prevalence of Chronic Pelvic Pain (CPP) in general population ranges between 5.7% and 26.6%(Ahangari, 2014). There are many countries and regions with no published data in the field of CPP (Ahangari, 2014). CPP is a great burden to the patients and the healthcare systems (Latthe et al., 2006). About £154 million was the estimated cost of treatment for the women who suffer from CPP per year (Cheong and William Stones, 2006). CPP affects one's movement and their posture due to the secondary hyperalgesia in the pelvic muscles leading to diminished proprioception. About 50%- 70% of women with CPP have limitation on their daily activity(Ahangari, 2014). PN occurs in men, but the incidence/prevalence is not well studied. The principle therapy for chronic neuropathic pain is to eliminate the underlying causes of the pain (Belgrade, 2003), for PN this may involve surgical decompression. Pharmacotherapy and physiotherapy are two different options for treatment of neuropathic pain but they each come with limitations and drawbacks. Different techniques for pudendal nerve block have been described for managing PN but they have complications that may be serious such, vascular injury or intravascular injection with toxicity. The indication of surgery is in patients with failure of conservative treatment or other PNB techniques / modalities and includes decompression or neuromodulation.

Type of the study: A retrospective randomized controlled study Study Setting: University college London hospital

Sample Size Calculation:

Sample size calculation was carried out using G*Power 3 software (Faul et al., 2007). A calculated minimum sample of the cases is 60 patients, 30 in each group.

Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …):

Total number of the cases is 60 patients, 30 in each group.

Intervention(s):

  1. Informed written consent: - A copy of the signed Informed Consent form will be given to the participant. The original signed form will be retained at the study site and a copy placed in the medical notes.
  2. The patient is placed in the prone position
  3. The ischial spine is then located using fluoroscopic X ray.
  4. Aseptic cleaning of the skin in the target area
  5. Patient will randomly be allocated to the control group receiving steroid and local anaesthetic injection or treatment group receiving pulsed radiofrequency treatment and local anaesthetic. Randomisation will be performed using sealed envelopes. I. Local anaesthetic and corticosteroid injection (control group) ▪ Under X-Ray guidance, the Needle (22G 5-10 cm insulated radiofrequency needle) is advanced perpendicular to the skin and placed transgluteally, directly avoiding the adjacent sciatic nerve at either the extremity of the ischial spine between the sacrotuberous and sacrospinous ligaments.
  • Sensory Electrostimulationis used to identify the nerve. For the motor stimulation, a unilateral contraction of the anal sphincter indicates that the inferior anal nerve had been stimulated while for the sensory stimulation, a sensation of tingling or numbness in the perineal region may be felt by the patient.
  • Contrast injected to avoid intravascular injection. A blinded operator sets the radiofrequency machine for a timer alert at five minutes.
  • After confirming the exact location of the needle tip, 4 mL of 1% lidocaine and 3.3 of dexamethasone in 1 mL are injected. II. Pulsed radiofrequency (Treatment/intervention group)
  • Needle is placed using the same technique as above and contrast medium is injected.
  • Lesion: - Radiofrequency current will be applied for 5 minutes, 120 ms, at 2 Hz, with maximum tissue temperature increased to 42°C. (usually not felt by the patient)
  • 4 mL of 1% lidocaine and 1 mL of NaCl .9% are injected.
  1. Post procedure instructions:- ▪ Standard post procedure monitoring for 1 hour in theatre recovery, including treatment of nausea/vomiting and localized pain with standard intravenous/oral medication.
  • Immediate adverse events reporting.
  • Standard hospital post procedure instructions

Research outcome measures:

  1. Primary Endpoint: Reduction in at least 1.5 point pain as measured by Numerical Rating Scale Secondary Endpoint A. NRS at 0, 1 and 12 weeks B Quality of Life Assessment at baseline, week 1, week 6 and week 12 a. EDQ5-5L b. SF-12 c. Brief Pain Inventory d. Global response Assessment C. Mood assessment at baseline, week 6 and week 12
  2. Pain Catastrophising Questionnaire b. Beck Depression Inventory II c. Hamilton Anxiety Rating Scale d. Sexual function assessment (questionnaire) at baseline, weeks 6 and 12 e. Lower urinary tract symptom assessment at baseline, weeks 6 and 12 f. Bristol Female Lower Urinary Tract Symptoms (BFLUTS-SF) g Review of pain medication use at weeks 6, 12 compared to baseline. h. Assessment of all patients against Nantes criteria at baseline 2.5-Data management and analysis (Details needed): Data collection. Telephone review - Week 1
  3. Telephone review in 1 week to assess for complication and side effcte profile.
  4. Global pelvic pain NRS scores over telephone.
  5. Adverse events reporting.
  6. Telephone review at 6 weeks and 12 weeks
  7. review pelvic pain
  8. Questionaires: global pelvic pain, QoL and function
  9. Medication review <!-- -->
  10. S - Study/Statistical design (e.g. randomised controlled trial, case control study, pilot study):
  11. Prospective
  12. Parallel group ( 2 different groups)
  13. No active Control
  14. Randomized
  15. Single blinded
  16. multicentric study (at UCLH center) Statistical methods:
  17. All data will be collected and cleaned by Excel program then will be analyzed with SPSS software (Statistical Package for the Social Sciences, version 16, SSPS Inc, and Chicago, USA). ii. Continuous parametric data between two groups, two sample T test will be used. iii. Continuous parametric data between more than 2 groups, ANOVA test will be used. iv. Descriptive statistics will be done in the form of mean and standard error (SE).
  18. Frequency of qualitative variables and Chi-square test will be done. vi. In Categorical data, Chi-squared test will be used.
Being tested
Injection, Radiofrequency
Keywords
Pelvic pain
Medical subject headings
Pudendal Neuralgia, Pelvic Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • InjectionDrug

    Injection of local anesthetic + steroids

  • RadiofrequencyDevice

    Application of radiofrequency on the diseased nerve

Study groups in NCT05531500
Study groupRoleWhat they receive
InjectionOtherInjection of local anesthetic and steroid to the diseased nerve
Receives: Drug: Injection
RadiofrequencyOtherApplication of radiofrequency to the diseased nerve
Receives: Device: Radiofrequency

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain score

    Pain score value from 1 to 10 reported by each individual patient following inter vention

    Measured: 6months 1 year after intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Sep 2022
  2. Study start9 Sep 2022 (estimated)
  3. Primary completion30 Apr 2023 (estimated)
  4. Study completion30 May 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
parallel groups of different intervention
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05531500
Sponsor's protocol ID
pelvic pain outcome
Acronym
pelvicpain
Status last verified
Sep 2022
First submitted
4 Sep 2022
Last updated
10 Sep 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Injection and Radiofrequency in people with Pudendal Neuralgia, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Medhat SA Farghaly, Master (2001095105568, medhatsradwan@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain score (time frame: 6months 1 year after intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in